In this study, we integrated data from the two different forms of G-CSF (filgrastim and lenograstim) together, because RCTs did not show any significant difference between filgrastim and lenograstim in terms of mobilization efficacy in both healthy donors and patients with hematological malignancies [52, 68, 94]. The gene discussed is CSF3; the disease is hematologic disorder.